Pace Ventures

Pace Ventures Enigma is a venture capital firm established in 2021 and located in Berlin, Germany. The firm focuses on investing in the climate-tech and health-tech sectors, targeting opportunities primarily in the United States and Europe. By concentrating on these critical areas, Pace Ventures aims to support innovative solutions that address pressing global challenges related to health and environmental sustainability.

Marius Swart

Managing Director and General Partner

9 past transactions

Vema Hydrogen

Seed Round in 2025
Vema Hydrogen is a trailblazing company specializing in clean hydrogen production. It tackles the global challenge of decarbonization by generating hydrogen through geologic stimulation, offering a clean and cost-effective alternative to traditional methods. The company employs advanced numerical simulations, geochemical analysis, and multiphase flow studies to optimize hydrogen production. It also identifies and tests suitable geological locations for pilot projects, obtains necessary permits, and optimizes catalyst use to enhance efficiency.

Dunia Innovations

Venture Round in 2024
Dunia Innovation is developing the world's first self-driving laboratory aimed at advancing electrocatalytic carbon dioxide utilization. This innovative facility is designed to significantly accelerate catalyst research, addressing the challenges associated with scalable carbon utilization. By focusing on creating a circular carbon economy, Dunia Innovation seeks to transform carbon dioxide into valuable chemicals and fuels. This approach not only helps businesses understand their carbon footprints but also supports the broader goal of achieving net-zero emissions by reducing overall emissions.

Turnover Labs

Pre Seed Round in 2024
Turnover Labs is focused on decarbonizing the chemical production sector by providing carbon-neutral alternatives to traditional petrochemicals. The company specializes in producing industrial chemicals using innovative electrocatalysts that can directly convert impure carbon dioxide waste streams from manufacturing processes into valuable chemical products on-site. This approach allows industries to effectively manage impurities, resulting in longer device lifetimes and reduced purification costs. As a result, Turnover Labs aims to make the synthesis of essential chemical building blocks more economical and sustainable, thereby transforming the way petrochemicals are generated.

Clearly.Earth

Seed Round in 2024
AI driven SaaS platform for smarter mobility emission management for fleet owners, operators and customers.

Neurable

Venture Round in 2024
Neurable Inc. is a neurotechnology company based in Cambridge, Massachusetts, founded in 2016. The company focuses on developing artificial intelligence software that translates brain activity into actionable insights, allowing users to control software and devices solely with their thoughts. Neurable's technology facilitates various applications, including gaming, operating toys, and driving vehicles, as well as enhancing experiences in virtual and augmented reality. By leveraging patented signal processing methods and a multidisciplinary approach that combines neuroscience, biology, statistics, and machine learning, Neurable aims to create high-performance brain-computer interfaces that are accessible and user-friendly.

Virtonomy

Venture Round in 2023
Virtonomy GmbH specializes in clinical trial services utilizing virtual models of humans and various animals, including sheep, pigs, and calves. Founded in 2019 and based in Munich, Germany, the company provides services such as anatomy studies, virtual fittings, pre-operative planning, and visualization through advanced image analysis and three-dimensional anatomical models. Its platform helps medical device manufacturers optimize designs, ensuring better patient outcomes by reducing risks associated with vessel misalignment and sizing inaccuracies. By offering insights into device-anatomy interactions, Virtonomy enables the development of patient-specific implants and enhances the overall evaluation of clinical interventions in a virtual setting. The company's innovative approach aims to streamline the medical device development process, ultimately accelerating the delivery of safe and effective products to the market.

Aerones

Series A in 2022
Aerones is a technology company founded in 2015 and headquartered in San Jose, California, specializing in robotic solutions for wind turbine blade maintenance. The company offers a range of automated services, including blade cleaning, de-icing, coating application, detailed inspections, data analysis, conductivity testing, and drainage hole cleaning and repair. Aerones' technology is designed to be compact and transportable, allowing for remote operation. This innovative approach enables wind energy businesses to conduct maintenance in an efficient, cost-effective, and safe manner, thereby enhancing the performance and longevity of wind turbines.

Aerones

Seed Round in 2022
Aerones is a technology company founded in 2015 and headquartered in San Jose, California, specializing in robotic solutions for wind turbine blade maintenance. The company offers a range of automated services, including blade cleaning, de-icing, coating application, detailed inspections, data analysis, conductivity testing, and drainage hole cleaning and repair. Aerones' technology is designed to be compact and transportable, allowing for remote operation. This innovative approach enables wind energy businesses to conduct maintenance in an efficient, cost-effective, and safe manner, thereby enhancing the performance and longevity of wind turbines.

Celeris Therapeutics

Seed Round in 2022
Celeris Therapeutics is an AI-driven drug discovery company focused on developing proximity-inducing compounds (PICs), particularly PIC degraders, to address diseases with significant unmet medical needs, including Parkinson's disease and various cancers. The company utilizes its proprietary Celeris One platform, which employs structure-based geometric deep learning to enhance the design and development of degraders. This platform aids in the prioritization of specific E3 ligases, the design of linkers, and the selection of the most promising compounds for synthesis. Additionally, Celeris Therapeutics operates an automated laboratory that rapidly generates experimental data for further optimization. The company collaborates with pharmaceutical and biotech firms to co-develop small-molecule degrader therapies across various therapeutic areas while also building its own drug pipeline. Celeris Therapeutics maintains offices in Menlo Park, California, and Graz, Austria.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.